1 |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
|
2 |
SIEGEL R L, WAGLE N S, CERCEK A, et al. Colorectal cancer statistics, 2023[J]. CA Cancer J Clin, 2023, 73(3):233-254.
|
3 |
XU L Y, ZHAO J H, LI Z H, et al. National and subnational incidence, mortality and associated factors of colorectal cancer in China: a systematic analysis and modelling study[J]. J Glob Health, 2023, 13: 04096.
|
4 |
LI N, LU B, LUO C Y, et al. Incidence, mortality, survival, risk factor and screening of colorectal cancer: a comparison among China, Europe, and northern America[J]. Cancer Lett, 2021, 522: 255-268.
|
5 |
HOSSAIN M S, KARUNIAWATI H, JAIROUN A A, et al. Colorectal cancer: a review of carcinogenesis, global epidemiology, current challenges, risk factors, preventive and treatment strategies[J]. Cancers, 2022, 14(7): 1732.
|
6 |
ZENG H M, RAN X H, AN L, et al. Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study[J]. Lancet Public Health, 2021, 6(12): e877-e887.
|
7 |
TESTA U, PELOSI E, CASTELLI G. Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells[J]. Med Sci, 2018, 6(2): 31.
|
8 |
MEZHEYEUSKI A, MICKE P, MARTÍN-BERNABÉ A, et al. The immune landscape of colorectal cancer[J]. Cancers (Basel), 2021, 13(21): 5545.
|
9 |
LIU S Z, GALAT V, GALAT Y, et al. NK cell-based cancer immunotherapy: from basic biology to clinical development[J]. J Hematol Oncol, 2021, 14(1): 7.
|
10 |
MYERS J A, MILLER J S. Exploring the NK cell platform for cancer immunotherapy[J]. Nat Rev Clin Oncol, 2021, 18(2): 85-100.
|
11 |
BRUNI D, ANGELL H K, GALON J. The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy[J]. Nat Rev Cancer, 2020, 20(11): 662-680.
|
12 |
TANG Y P, XIE M Z, LI K Z, et al. Prognostic value of peripheral blood natural killer cells in colorectal cancer[J]. BMC Gastroenterol, 2020, 20(1): 31.
|
13 |
MENON A G, JANSSEN-VAN RHIJN C M, MORREAU H, et al. Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis[J]. Lab Invest, 2004, 84(4): 493-501.
|
14 |
DONADON M, HUDSPETH K, CIMINO M, et al. Increased infiltration of natural killer and T cells in colorectal liver metastases improves patient overall survival[J]. J Gastrointest Surg, 2017, 21(8): 1226-1236.
|
15 |
HALAMA N, BRAUN M, KAHLERT C, et al. Natural killer cells are scarce in colorectal carcinoma tissue despite high levels of chemokines and cytokines[J]. Clin Cancer Res, 2011, 17(4): 678-689.
|
16 |
COPPOLA A, ARRIGA R, LAURO D, et al. NK cell inflammation in the clinical outcome of colorectal carcinoma[J]. Front Med (Lausanne), 2015, 2: 33.
|
17 |
SORRENTINO C, D'ANTONIO L, FIENI C, et al. Colorectal cancer-associated immune exhaustion involves T and B lymphocytes and conventional NK cells and correlates with a shorter overall survival[J]. Front Immunol, 2021, 12: 778329.
|
18 |
JOBIN G, RODRIGUEZ-SUAREZ R, BETITO K. Association between natural killer cell activity and colorectal cancer in high-risk subjects undergoing colonoscopy[J]. Gastroenterology, 2017, 153(4): 980-987.
|
19 |
GANESH K, STADLER Z K, CERCEK A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential[J]. Nat Rev Gastroenterol Hepatol, 2019, 16(6): 361-375.
|
20 |
BAI Z Y, ZHOU Y, YE Z F, et al. Tumor-infiltrating lymphocytes in colorectal cancer: the fundamental indication and application on immunotherapy[J]. Front Immunol, 2021, 12: 808964.
|
21 |
DE VISSER K E, JOYCE J A. The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth[J]. Cancer Cell, 2023, 41(3): 374-403.
|
22 |
MASKALENKO N A, ZHIGAREV D, CAMPBELL K S. Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders[J]. Nat Rev Drug Discov, 2022, 21(8): 559-577.
|
23 |
CRINIER A, NARNI-MANCINELLI E, UGOLINI S, et al. SnapShot: natural killer cells[J]. Cell, 2020, 180(6): 1280-1280.e1.
|
24 |
HASHEMI E, MALARKANNAN S. Tissue-resident NK cells: development, maturation, and clinical relevance[J]. Cancers, 2020, 12(6): 1553.
|
25 |
DOGRA P, RANCAN C, MA W J, et al. Tissue determinants of human NK cell development, function, and residence[J]. Cell, 2020, 180(4): 749-763.e13.
|
26 |
CAPUANO C, PIGHI C, BATTELLA S, et al. Harnessing CD16-mediated NK cell functions to enhance therapeutic efficacy of tumor-targeting mAbs[J]. Cancers, 2021, 13(10): 2500.
|
27 |
MEI Y, XIAO W W, HU H, et al. Single-cell analyses reveal suppressive tumor microenvironment of human colorectal cancer[J]. Clin Transl Med, 2021, 11(6): e422.
|
28 |
MERINO A M, KIM H, MILLER J S, et al. Unraveling exhaustion in adaptive and conventional NK cells[J]. J Leukoc Biol, 2020, 108(4): 1361-1368.
|
29 |
GAO L, DU X H, LI J B, et al. Evolving roles of CD38 metabolism in solid tumour microenvironment[J]. Br J Cancer, 2023, 128(4): 492-504.
|
30 |
GARS M L, SEILER C, KAY A W, et al. CD38 contributes to human natural killer cell responses through a role in immune synapse formation[Z/OL]. bioRxiv, 2018[2023-11-16]. https://www.biorxiv.org/content/10.1101/349084v2#:~:text=CD38%20localizes%20and%20accumulates%20at%20the%20immune%20synapse,critical%20 role%20in%20NK%20cell%20immune%20synapse%20formation.
|
31 |
WEISER M R. AJCC 8th edition: colorectal cancer[J]. Ann Surg Oncol, 2018, 25(6): 1454-1455.
|
32 |
DWIVEDI S, RENDÓN-HUERTA E P, ORTIZ-NAVARRETE V, et al. CD38 and regulation of the immune response cells in cancer[J]. J Oncol, 2021, 2021: 6630295.
|